SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it intends to offer and sell, subject to market and
other conditions, $200,000,000 of its common stock in an underwritten
public offering. There can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynch
are acting as the joint book-running managers for the offering. ACADIA
intends to grant the underwriters a 30-day option to purchase an
additional $30,000,000 of its common stock.
The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement filed by ACADIA with the
Securities and Exchange Commission (SEC) that became automatically
effective on March 3, 2014. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus related to this offering, when available, may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204, or by email to: email@example.com,
or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or by
email to: firstname.lastname@example.org,
or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by
email to: email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders.
Statements in this press release that are not strictly historical in
nature, including statements related to the proposed offering of common
stock by ACADIA, are forward-looking statements. These statements are
only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or results
may differ materially from those projected in any of such statements due
to various factors, including market risks and uncertainties and the
satisfaction of customary closing conditions for an offering of
securities. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2015
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160808006143/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Senior
Director, Investor Relations